The approval of Rasonque (daraxonrasib) gave second-line metastatic pancreatic cancer its first RAS-targeted option. It also turned a company that has never sold anything into a commercial one, without a pharma partner and about six months earlier than the review calendar said it would need to be ready.
The clinical case was settled at ASCO in May. What opens now is narrower: whether the drug’s behavior in clinic translates into a launch that funds everything standing behind it.
The Label Is Wider Than the Trial
RASolute 302 enrolled patients with ECOG performance status 0 or 1 who had received one prior fluoropyrimidine- or gemcitabine-containing regimen. The label extends beyond the exact population enrolled in RASolute 302, including real-world patients who may have poorer performance status or limited treatment options.
Unlike mutation-specific inhibitors requiring confirmation of a single alteration, daraxonrasib does not require biomarker testing before prescribing under the approved indication. Enrollment was open regardless of RAS status, benefit held in the intent-to-treat population, and nothing in the label gates prescribing on a test result. For a community practice, that removes the tissue-and-turnaround problem that governs use of mutation-specific inhibitors. For the company, it removes a diagnostic bottleneck between approval and first prescription.
Price, and the Duration That Has to Justify It
Rasonque lists at $39,800 for a 30-day supply. The clinical number that sits next to it is median time on treatment: 6.2 months on daraxonrasib against 1.5 to 3.2 months across the chemotherapy comparators, with 42% of the daraxonrasib arm still on drug at the February cutoff versus 14% on chemotherapy.
That gap is the drug’s clinical advantage and its commercial engine at the same time. Patients stayed on it because they could, median dose intensity 93.1%, discontinuation for treatment-related toxicity 1.2% versus 11.2%, and every month of that persistence is also a month of revenue. It moves these patients out of the infusion suite and onto a once-daily tablet, changing how practices are paid for treating them as well as how they are treated.
Nothing about net price or payer policy is public yet. In a Medicare-heavy, symptomatic population, prior authorization turnaround and time to first fill will shape the launch curve more than the list figure will.
The Choice Not to Partner
A phase 3 pancreatic asset with a hazard ratio of 0.40 is the kind of thing large pharma buys. Revolution Medicines, founded in October 2014, declined to sell it.
It went to Royalty Pharma instead, in June 2025, for $2 billion: up to $1.25 billion in synthetic royalties on daraxonrasib sales plus a senior secured term loan of up to $750 million. The stated reason was control, capital that cost no development or commercialization rights. The loan’s first $250 million tranche must be drawn following approval in metastatic pancreatic cancer, which makes Wednesday a financing trigger as much as a regulatory one. Another $2.225 billion arrived in April through equity and convertible offerings. The company entered launch with $3.9 billion in cash against full-year operating expense guidance of $2.1 to $2.2 billion.
A Launch Built Before the Approval
The FDA accepted the NDA on July 22 and approved it 35 days later, 6.5 months ahead of the user fee date, under the Commissioner’s National Priority Voucher pilot, a program that had produced seven approvals against roughly 22 vouchers issued as of this spring, and whose compressed timelines mean commercial readiness now has to exist before the review that used to supply the time to build it.
Revolution Medicines had been building since spring. It opened an FDA-cleared expanded access program in May, was shipping within three weeks, and by August 5 had supplied physicians treating more than 2,000 patients across academic and community sites in nearly all 50 states and Puerto Rico. The commercial value of that is a mapped prescriber base. The clinical value may matter more: months of community experience managing the rash and stomatitis that drove most dose reductions in the trial, accumulated before the first commercial prescription was written.
What the Valuation Is Pricing
At roughly $45 billion, the market is not paying for second-line pancreatic cancer. Attrition from first line is steep, and even a well-tolerated oral agent only reaches the patients who get there. It is paying for the settings where the population is larger and the disease less advanced.
RASolute 303 and 304 are testing daraxonrasib in first-line metastatic and adjuvant disease. RASolve 301, in previously treated RAS-mutant NSCLC, completes enrollment this year with a first readout expected in 2027. Behind them sit the mutant-selective inhibitors and the RAS(ON) doublets, RASolute 309 pairs zoldonrasib with daraxonrasib in G12D pancreatic cancer, along with first-line lung combinations on checkpoint and platinum backbones now moving into phase 3.
The unanswered clinical questions are the ones that will decide all of it. Median follow-up was 8.5 months, so the tail of the curve is undrawn. Nobody yet knows what to give after daraxonrasib, or what resistance to a multi-selective RAS(ON) inhibitor looks like. And whether the drug holds up in the poorer-performance-status patients the label permits but the trial excluded will be learned in clinic, not in a registration study.
The scientific question, whether RAS can be drugged in its active state, was answered in May. The one that opened Wednesday is whether a twelve-year-old company can run a launch, hold a price, and fund a phase 3 portfolio at once, on no balance sheet but its own. That one won’t be settled in a plenary session. It will be settled by prescription data and quarterly results.
Read further on the FDA’s Approval of Daraxonrasib on OncoDaily.
Read more biotech insights on OncoDaily Biotech.
Written by: Semiramida Nina Markosyan, Editor, OncoDaily Canada